Reference

Combinations of eszopiclone and an antidepressant, for treatment of menopause and mood, anxiety, and cognitive disorders

All Rights Reserved. Combinations of eszopiclone and an antidepressant, for treatment of menopause and mood, anxiety, and cognitive disorders. Caron, Judy; Wessel, Thomas; Lalji, Karim; Varney, Mark A. (Sepracor Inc., USA). PCT Int. Appl. WO 2007005962 A2 11 Jan 2007, 44pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IS, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). (World Intellectual Property Organization). CODEN: PIXXD2. APPLICATION: WO 2006-US26186 5 Jul 2006. PRIORITY: US 2005-696976P 6 Jul 2005. DOCUMENT TYPE: Patent CA Section: 63 (Pharmaceuticals) Section cross-reference(s): 1 One aspect of the present invention relates to pharmaceutical compns. contg. 2 or more active agents that when taken together can be used to treat, e.g., menopause, mood disorders, anxiety disorders, or cognitive disorders. The first component of the pharmaceutical compn. is a sedative eszopiclone. The second component of the pharmaceutical compn. is an antidepressant. 138729-47-2 and 71620-89-8 which are cas registry numbers of chemicals are mentioned. The present invention also relates to a method of treating menopause, perimenopause, mood disorders, anxiety disorders, and cognitive disorders. Thus, a capsule contained eszopiclone 3.00, fluoxetine-HCl 11.20,, Avicel PH102 198.90, dibasic calcium phosphate 90.00, Croscarmellose sodium 6.00, colloidal silica 0.60, and Mg stearate 1.50 mg/unit. .

A polysomnography study of eszopiclone in elderly patients with insomnia

All Rights Reserved. A polysomnography study of eszopiclone in elderly patients with insomnia. McCall, W. Vaughn; Erman, Milton; Krystal, Andrew D.; Rosenberg, Russell; Scharf, Martin; Zammit, Gary K.; Wessel, Thomas (Wake Forest University Health Sciences, Winston-Salem, NC, USA). Current Medical Research and Opinion, 22(9), 1633-1642 (English) 2006 LibraPharm Ltd. CODEN: CMROCX. ISSN: 0300-7995. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) Objective: To evaluate the safety and efficacy of eszopiclone 2 mg in elderly patients (aged 64-86 years) with chronic insomnia. Methods: This was a randomized, double-blind, placebo-controlled 2-wk study. Patients meeting DSM-IV criteria for primary insomnia and screening polysomnog. criteria (wakefulness after sleep onset [WASO] 3 20 min and latency to persistent sleep 3 20 min) were randomized to 2 wk of nightly treatment with eszopiclone 2 mg (n = 136) or placebo (n = 128).Some commonly used reagents like 138729-47-2 is used in this experiment. Efficacy was assessed using polysomnog. (Nights 1, 2, 13, and 14) and patient reports (Nights 1-14); safety was assessed using adverse events, clin. labs, phys. examn., and vital signs. The mean of all efficacy results during the double-blind period was used for the efficacy anal. Results: Results indicated that eszopiclone was assocd. with significantly shorter sleep onset, less WASO, higher sleep efficiency, more total sleep time, and greater patient-reported quality and depth of sleep scores than placebo (p < 0.05 for all) with a trend in patient-reported morning sleepiness (p = 0.07). Other measures of daytime functioning (ability to function, daytime alertness, and sense of well-being) were not significantly different between the two treatment groups. Among patients who napped, eszopiclone patients reported fewer naps (p = 0.03) and less cumulative naptime (median: 98 min placebo, 70 min eszopiclone, p = 0.07). Unpleasant taste, dry mouth, somnolence, and dizziness were higher in the eszopiclone group (12.5%, 8.8%, 6.6%, and 6.6%, resp.) than in the placebo group (0%, 1.6%, 5.5%, and 1.6%, resp.). Conclusion: In this study, eszopiclone was well tolerated and produced significant improvements in both polysomnog. and patient-reported measures of sleep maintenance, sleep induction, and sleep duration in elderly patients with chronic primary insomnia. .